Summary
Exposure bracketing is a widely used strategy in clinical pharmacology to optimize dosing for targeted patient populations. In many programs, these brackets must be extrapolated from prior human and animal studies to define the minimum and maximum safe and efficacious dose ranges for a given therapy and treatment paradigm.
Traditionally, this requires a labor-intensive and time-consuming review of internal and external studies to manually extract the necessary PK/PD data. Recent advances in artificial intelligence (AI) now provide a compelling alternative: automating the ingestion of large volumes of unstructured data from reports, presentations, and publications and transforming them into analysis-ready datasets.
Sign up today for our live webinar on February 18, 2026 for an in-depth discussion on how emerging AI techniques, such as prompt chaining, can streamline and scale data aggregation in clinical pharmacology workflows.
What you’ll learn
- How structured AI workflows can model agentic AI behavior in a deterministic and transparent manner
- How LLM prompt chaining can convert unstructured study content into usable datasets for exposure bracketing
- Best practices for implementing AI-driven data extraction pipelines while maintaining data integrity and accuracy
Register now
Sean McGee, MS
Director of Product, CertaraSean McGee is currently the Director of Product at Certara, working within the Certara artificial intelligence (AI) group. Throughout his career, Mr. McGee has supported the strategy and go-to-market motions of various software technologies, including Benchling’s laboratory informatics platform and the AI and molecular modeling and simulation offerings for Dassault Systèmes BIOVIA brand. In his role with Certara, Mr. McGee guides the development of new AI-focused use cases which maximize the benefits of the Certara AI and broader company portfolio.
Mr. McGee completed his Master of Science at the University of Notre Dame exploring the scientific and commercial applications of medical devices designed to aid in the identification of child abuse.
Racheal Kendrick, PharmD
Director of Clinical Pharmacology and Translational Medicine Certara Drug Development SolutionsDr. Racheal Kendrick is currently a Director of Clinical Pharmacology and Translational Medicine at Certara. She has 15 years of drug development experience with a focus on quantitative solutions using state of the art methods and software. Racheal has contributed to all phases of the drug development cycle including first in human dose selection, IND support, Phase I study design, strategy, and implementation, dose-finding approaches, exposure-response analyses, and regulatory interactions. Racheal has experience collaborating with teams of scientific professionals from some of the worlds major pharmaceutical and biotechnology companies in many therapeutic areas including neurology, ophthalmology, infectious disease, oncology, hematology, and contraception, advancing both large and small molecules.
Prior to her role at Certara, Racheal was an associate director at a contract research organization, with a focus on Phase I studies. Racheal received her Doctor of Pharmacy from the University of Missouri-Kansas City and completed a pharmacokinetics and pharmacodynamics fellowship with the University of North Carolina and Quintiles.
Register now
